| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $5,487 | 1 | 100 |
Sells | $0 | 0 | 0 |
| KAITIN KENNETH I | director | 1 | $5,487 | 0 | $0 | $5,487 |
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company’s pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with …
Over the last 12 months, insiders at Curis, Inc. have bought $5,487 and sold $0 worth of Curis, Inc. stock.
On average, over the past 5 years, insiders at Curis, Inc. have bought $5,487 and sold $17,150 worth of stock each year.
Highest buying activity among insiders over the last 12 months: KAITIN KENNETH I (director) — $5,487.
The last purchase of 10,000 shares for transaction amount of $5,487 was made by KAITIN KENNETH I (director) on 2026‑03‑31.
| 2026-03-31 | KAITIN KENNETH I | director | 10,000 0.0761% | $0.55 | $5,487 | -55.62% | ||
| 2022-01-31 | Sale | Dentzer James E | President & CEO | 3,094 0.0032% | $3.07 | $9,499 | -70.22% | |
| 2022-01-27 | Sale | Dentzer James E | President & CEO | 2,406 0.0027% | $3.18 | $7,651 | -68.40% | |
| 2021-01-26 | Sale | Dentzer James E | President & CEO | 3,094 0.0036% | $10.59 | $32,758 | -21.62% | |
| 2021-01-25 | Sale | Dentzer James E | President & CEO | 2,283 0.0027% | $10.96 | $25,022 | -23.56% | |
| 2020-01-24 | Sale | Dentzer James E | President & CEO | 3,094 0.0087% | $1.64 | $5,076 | -29.41% | |
| 2020-01-23 | Sale | Dentzer James E | President & CEO | 3,658 0.0109% | $1.69 | $6,182 | -27.27% | |
| 2019-01-24 | Sale | Dentzer James E | President & CEO | 3,094 0.0082% | $1.16 | $3,577 | +36.36% | |
| 2019-01-23 | Sale | Dentzer James E | President & CEO | 2,397 0.0074% | $1.09 | $2,613 | +68.22% | |
| 2019-01-23 | Sale | Rubin Marc | director | 18,500 0.0549% | $1.05 | $19,477 | +68.22% | |
| 2019-01-23 | Sale | KAITIN KENNETH I | director | 14,800 0.0439% | $1.05 | $15,587 | +68.22% | |
| 2019-01-23 | Sale | GREENACRE MARTYN D | director | 18,500 0.0549% | $1.05 | $19,475 | +68.22% | |
| 2019-01-23 | Sale | Martell Robert | Head of Research & Development | 5,500 0.0166% | $1.07 | $5,900 | +68.22% | |
| 2019-01-23 | Sale | Kunkel Lori Anne | director | 14,800 0.0439% | $1.05 | $15,581 | +68.22% | |
| 2017-11-16 | Rubin Marc | director | 25,000 0.0176% | $0.98 | $24,500 | -47.17% | ||
| 2017-11-15 | Fattaey Ali Ph.D. | President & CEO | 50,000 0.036% | $1.06 | $53,000 | -49.76% | ||
| 2017-05-05 | Sale | MCNAB JAMES R | director | 16,176 0.0113% | $1.90 | $30,721 | -20.63% | |
| 2017-05-04 | Sale | MCNAB JAMES R | director | 30,100 0.0213% | $1.97 | $59,159 | -22.22% | |
| 2017-05-03 | Sale | MCNAB JAMES R | director | 30,000 0.0213% | $2.18 | $65,544 | -29.21% | |
| 2017-05-02 | Sale | MCNAB JAMES R | director | 35,646 0.0249% | $2.31 | $82,314 | -33.48% |
| Increased Positions | 12 | +25% | 284,994 | +6.18% |
| Decreased Positions | 14 | -29.17% | 567,041 | -12.29% |
| New Positions | 5 | New | 169,386 | New |
| Sold Out Positions | 5 | Sold Out | 10,353 | Sold Out |
| Total Postitions | 46 | -4.17% | 4M | -6.11% |
| Bleichroeder Lp | $1,116.00 | 8.74% | 1.14M | +100,000 | +9.66% | 2025-09-30 |
| Armistice Capital, Llc | $962.00 | 7.53% | 978,190 | +78,265 | +8.7% | 2025-09-30 |
| Citigroup Inc | $571.00 | 4.47% | 581,118 | +489,246 | +532.53% | 2025-09-30 |
| M28 Capital Management Lp | $512.00 | 4.01% | 521,059 | 0 | 0% | 2025-09-30 |
| Vanguard Group Inc | $361.00 | 2.83% | 367,619 | +64,428 | +21.25% | 2025-09-30 |
| Cm Management, Llc | $319.00 | 2.5% | 325,000 | +105,000 | +47.73% | 2025-09-30 |
| Renaissance Technologies Llc | $173.00 | 1.35% | 175,513 | +75,041 | +74.69% | 2025-09-30 |
| Geode Capital Management, Llc | $93.00 | 0.73% | 94,671 | +9,363 | +10.98% | 2025-09-30 |
| Focused Wealth Management, Inc | $78.00 | 0.61% | 79,199 | +19,995 | +33.77% | 2025-09-30 |
| Squarepoint Ops Llc | $58.00 | 0.46% | 59,140 | +8,973 | +17.89% | 2025-09-30 |